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845-6 Dexrezoxene Is Cardloprotective Against Doxorubicin 
Cardlotoxlclty 
Steven E. LiDshultz, Nader Rifai, Virginia Dalton, Donna Levy, Stuart R. Lipsitz, Richard 
D. Gelber, Steven D. Colan, Seema Shaikh, Stephen E. Sallan, For the Dana-Farber 
Cancer Institute Protocol 95-001 Childhood ALL Consortium Study Investigators, 
University of Rochester, Rochester, New York, Dana-Farber Cancer Institute and 
Children's Hospital, Boston, Massachusetts. 
Background: Doxorubicin (DOX)-related myocardial injury has become a pervasive, 
persistent, and progressive problem in many survivors of childhood acute lymphoblastic 
leukemia (ALL). 
Methods: A blinded randomized prospective study of dexrazoxane (DEX, Zinecard), a 
free-radical scavenger, administered at 10 [DEX]:I[DOX] ratio IV 30 rain prior to each 
DOX dose (30 mg/m2/dose very 3 weeks x 10 doses), was conducted in 150 newly 
diagnosed pts with ALL at 10 US/Canadian centers from 1995-2001 to determine if DEX 
was cardioprotactive. Acute myocardial injury was measured by elevated (>.01 ng/ml) 
serum cardiac troponin T (cTnT) levels (Elecsys Troponin T assay). 
Results: Children randomized to DEX/DOX (N=74) had 16 cTnT samples (median, 
range, 1-32, 47.3% with >~20) with a median cTnT level of 0 ng/ml (range, 0-.161 ng/ml, 
mean, .0156 ng/ml, SD, .034 ng/ml, total # of elevated cTnT samples, 74/1284 [5.8%]). 
Children randomized to DOX (N=76) had a median of 14 cTnT samples (range, 1-33, 
31.6% with ~ 20) with a median cTnT level of .01 ng/ml (range, 0-.194 ng/ml, mean, 
.0211 ng/ml, SD, .037 ng/ml, total # of elevated cTnT samples, 138/1146 [12%]}. There 
were no significant differences (P=I.0) in the % of cTnT elevations before DOX in pts 
randomized to DEX/DOX (6/55 pts) and the pts randomized to DOX alone (6/48 pts). The 
DEX/DOX pts had a significantly lower % of pts with cEnT elevations than the DOX pts 
(DEX/DOX=17/74 pts [23%] vs. DOX=34/75 pts [45.3%], P=.0055, the % of pts with 
cTnT elevations after DOX therapy has ended (DEX/DOX=4/30 pts [13.3%] vs. DOX=13/ 
34 pts [38.2%], P=.043), the % of pts with _>1 elevated cTnT sample (DEX/DOX=18/74 
pts [24.3%] vs. DOX 36/76 pts [47.4%], P=.0039, the percentage of pts with - f sample 
with higher elevation of cTnT (>.025 ng/ml) (DOXJDEX=10/74 pts [13.5%] vs. DOX=21/ 
76 [27.6%], P=.0433), and in the percentage of non-infant pts who received ->60 mg/m 2 
of DOX with >1 elevated cTnT sample (DEX/DOX=14/65 pts ]21.5%] vs. DOX=32/68 pts 
[47.1%], P=.0033). 
Conclusion: Dexrazoxane therapy significantly reduced acute myocardial injury in chil- 
dren receiving DOX. This cardioprotective therapy may be useful in other states of pedi- 
atric myocardial injury. 
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847-1 Do AHA Antibiotic Prophylaxis Guidelines for 
Prevention of Antibiotics Need Revision? 
Jodi Indes, Robert Shapiro, Lori B. Croft. Anthony Squire, Jennifer Pennipede, Samantha 
Buckley, Martin E. Goldman, Mt. Sinai Medical Center, New York, New York. 
i}sckoround: The American Heart Association (AHA) promulgated guidelines for antibi- 
otic prophylaxis for prevention of endocarditis for pts. The FDA refined the guidelines fur- 
ther to include: valvular stenosis (mitral, aortic or tricuspid), > 2+ (mild/moderate) valvular 
regurgitation, mitral valve prolapse with at least mild regurgitation, congenital esions and 
prosthetic valves. As subjects age their valves may fibrose/calcify and develop stenosis/ 
regurgitation which would qualify them for prophylaxis, However, the use of antibiotics 
has associated risks such as anaphylaxis, and tachyphylaxis. Methods: Thus, to deter- 
mine the number of older subjects who would qualify for antibiotic prophylaxis, we 
reviewed 600 echocardiograms performed with the latest echo technology. Results: We 
found that there was a significant increase in the incidence of valve lesions requiring pro- 
phylaxis as subjects aged (p<.0001); Greater than 50% of subjects over 60 yr old would 
require treatment. Whether our findings are due to newer generation, higher resolution 
echocardiographic systems that can detect more abnormalities than prior systems or the 
progression of cardiac disease with aging is unclear. Conclusion: Indications for antibi- 
otic prophylaxis are found in a majority of pts > 60 yr old. The implications of our study 
warrant further evaluation of the current guidelines as we witness the "graying" of Amer- 
ica. 
Aoe~vrai 20-40 40-60 60-80 80-100 
Total pts 73 190 238 99 
Positive 17 61 112 65 
% Positive 23% 21% 47% 66% 
847:2 Is Pr imary Angioplaety Better Than Thrombolytic 
Therapy in Elderly Patients With Acute Myocardial 
Infarction? An Insight From the Global Registry of 
Acute Coronary Events (GRACE) 
Raiendra H. Mehta, Kim A. Eagle, Eva Kline-Rogers, Robert J. Goldberg, Joel M. Gore, 
AIvaro Avezum, Keith A. Fox, Frederick Spencer, Jeanna Johnson, Immad Sadiq, on 
behalf of the GRACE Investigators, University of Michigan Health System, Ann Arbor, 
Michigan. 
Background Few data exist on the effectiveness of primary percutaneous coronary 
interventions (PCI) over thrombolytio therapy (TT) in eldedy with acute myocardial infarc- 
tion (AMI) in the era of stents and antithrombotic agents from a community based per- 
spective. 
Methods We evaluated data from AMI patients aged _>65 years (ST-elevation or left bun- 
dle branch block on ECG) enrolled in GRACE. 
Results A total of 2212 elderly AMI patients were eligible per standard reperfusion ther- 
apy criteria. Of these, 253 (11.4%) received primary PCI and 700 (31.7%) "iT (median 
age 74 vs 73 years). Median delay to primary PCI was 121 rain (IQR 65, 330 rain) and to 
"IF 40 rain (IQR 25, 70 min; p<0.001). Primary PCI patients were more likely to have dia- 
betes, prior PCI, prior stroke and KiUip class _>11. Similady, the newer antithrombotic 
agents (clopidogrel, ticlopidine, low molecular weight hepafins and glycoprotein itbllla 
antagonists) were used more frequently in primary PCI patients. Hospital complications 
for primary PCI vs TT were: mortality 8.9% vs 13.4%, p=0.06; re-AMI 1.2% vs 6.1%, 
p=O.O02; major bleeding 6.6% vs 4.4%, p=0.17; and stroke 1.2% vs 2.3%, p=0.29. Odds 
ratios for primary PCI with reference to patients treated with l-r (adjusted for differences 
in baseline characteristics) are as shown (Table). 
Conclusions Primary PCI in elderly AMI patients, in a community setting, is associated 
with decreased adjusted hospital mortality and reinfarction, but with no difference in the 
adjusted outcome of stroke or major bleed. 
Outcome Adjusted odds ratio 95% Confidence Interval P value 
Death 0.425 0.239-0.755 0.0035 
Reinfarction O. 159 0.189-0.526 0.0026 
Stroke 0.698 0.189-2.572 0.5887 
Major bleed 1.538 0,779-3.040 0.2151 
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847-3 Is Quality of Life Enhanced in Octogenarians 
Undergoing Coronary Artery Bypass Surgery? 
Paul Kudanskv. Donald B. Williams, Ernest A. Traad, Roger G. Carrillo, John S. Schor, 
Melinda Zucker, George Ebra, Miami Heart Research Institute, Miami Beach, Florida, 
Mount Sinai Medical Center, Miami Beach, Florida. 
Background: Octogenarians comprise the fastest growing segment of our population. 
With over 40% manifesting some form of cardiovascular disease, coronary bypass sur- 
gery (CABG) is increasingly recommended. Does the observed long-term clinical out- 
come and qualify of life (QOL) warrant surgical intervention in this high-risk elderly 
group? 
Methods: Retrospective analysis was conducted on 1000 consecutive patients undergo- 
ing CABG from 1982-2000. Follow-up ranged from one month to 19 years (mean=3.6 
years). The SF-36 OOL survey was administered to all survivors at the time of last follow- 
up, which was 97.5% complete. 
Results: Mean age was 83.1 (range 80-99). There were 393 (39.3%) women, 693 
(89.3%) patients with triple vessel disease, 565 (56.5%) with reduced ejection fraction 
(EF<50%), 213 (21.3%) who underwent urgent or emergent surgery, and 956 (95.6%) 
with NYHA Class itl or IV symptoms. Hospital mortality was 9.0% (90/1000), with 67.2% 
(672/1000) free of post-op complications. Actuarial surviva) for patients discharged from 
the hospital was 63±1.9% at 5 years and 21.7+2.8% at 10 years. Multivariate predictors 
of late mortality included a history of congestive heart failure (p=0.002), absence of an 
internal mammary artery graft (p=0.002), prolonged pertusion time (p=0.050), renal dys- 
function (p=0.001), peripheral vascular disease (p=0.011) and three vessel disease 
(p=O.016), At follow-up, 89.2% (445/499) were angina free, and 98.2% (490/499) were 
free of major adverse cardiac events. The SF-36 revealed scores equal to or better than 
age-matched controls in seven of eight health scales measured. Study group and con- 
trols were similar in both physical (38.8+10.9 vs. 38.0±11.2; p=0.173) and mental 
(50.9"J:10.4 vs. 50.4±11.7; p=0.280) health summary scores. Similar or improved health 
status compared with one year previously was reported by 77.6% (382/491) of patients. 
Conclusion: CABG surgery in octogenarians has a favorable pedoperative and long- 
term clinical outcome. Despite the higher risks and shorter longevity of this group, both 
clinical and patient-perceived QOL are excellent, and justify surgical intervention. 
